Research programme: covalent inhibitors - Aurigene Discovery Technologies

Drug Profile

Research programme: covalent inhibitors - Aurigene Discovery Technologies

Alternative Names: AU-002; CDK12 inhibitors; CDK7 inhibitor; KRAS inhibitor; MALT-1 inhibitor

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CD7 antigen inhibitors; Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; KRAS protein inhibitors; MALT1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Oct 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017 (AACR-NCI-EORTC-2017)
  • 15 Apr 2016 Preclinical trials in Cancer in India (PO) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top